CMS is expected to announce in early 2025 the list of up to 15 Medicare Part D drugs that will be subject to price negotiations in 2025, with negotiated prices expected to be implemented in 2027.
Researchers have aimed to predict which drugs would be selected by analyzing Part D spending from 2020 to 2022 and applying selection criteria from the Inflation Reduction Act and CMS guidelines.
The 13 drugs most likely to be chosen for CMS negotiations, according to the study:
- Ozempic, Rybelsus and Wegovy (semaglutide): Novo Nordisk's treatment for Type 2 diabetes and weight management.
- Trelegy Ellipta (fluticasone/umeclidinium/vilanterol): A GlaxoSmithKline inhaler for chronic obstructive pulmonary disease.
- Xtandi (enzalutamide): A prostate cancer treatment from Astellas Pharma.
- Ofev (nintedanib): A Boehringer Ingelheim drug used to treat lung diseases such as idiopathic pulmonary fibrosis.
- Pomalyst (pomalidomide): A Bristol Myers Squibb medication for blood cancers, including multiple myeloma.
- Ibrance (palbociclib): Pfizer's drug for hormone receptor-positive, HER2-negative breast cancer.
- Linzess (linaclotide): A gastrointestinal therapy by AbbVie used to treat irritable bowel syndrome with constipation.
- Calquence (acalabrutinib): A blood cancer treatment from AstraZeneca, primarily for mantle cell lymphoma and chronic lymphocytic leukemia.
- Creon (pancrelipase): AbbVie's enzyme replacement therapy for pancreatic insufficiency.
- Breo Ellipta (fluticasone/vilanterol): A GlaxoSmithKline inhaler for chronic obstructive pulmonary disease and asthma.
- Tradjenta (linagliptin): A Boehringer Ingelheim treatment for Type 2 diabetes.
- Janumet (metformin/sitagliptin): Merck's combination therapy for Type 2 diabetes.
- Austedo (deutetrabenazine): A drug from Teva Pharmaceuticals for treating chorea associated with Huntington's disease and tardive dyskinesia.